Evidence map›Paper›PMID 38957161›Full record

ArticleNeuro-oncology advances

Imaging meningioma biology: Machine learning predicts integrated risk score in WHO grade 2/3 meningioma.

Olivia Kertels, Claire Delbridge, Felix Sahm, Felix Ehret, Güliz Acker, David Capper, Jan C Peeken, Christian Diehl, Michael Griessmair, Marie-Christin Metz and 12 more

Abstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Advancements in the application of MRI radiomics in meningioma.Radiation oncology (London, England) · 2025
    Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Olivia KertelsDepartment of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Claire DelbridgeDepartment of Neuropathology, School of Medicine, Institute of Pathology, Technical University of Munich, Munich, Germany.
Felix SahmDepartment of Neuropathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID https://orcid.org/0000-0001-5441-1962
Felix EhretGerman Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID https://orcid.org/0000-0001-6177-1755
Güliz AckerDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
David CapperGerman Cancer Consortium (DKTK), Partner Site Berlin, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID https://orcid.org/0000-0003-1945-497X
Jan C PeekenDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Institut für Innovative Radiotherapy (iRT), Munich, Germany.
Christian DiehlDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Institut für Innovative Radiotherapy (iRT), Munich, Germany.
Michael GriessmairDepartment of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
Marie-Christin MetzDepartment of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-1459-5741
Chiara NegwerDepartment of Neurosurgery, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany.
Sandro M KriegDepartment of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany.
Julia OnkenDepartment of Neurosurgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Igor YakushevDepartment of Nuclear Medicine, Klinikum Rechts der Isar, Technical University of Munich, München, Germany.
Peter VajkoczyDepartment of Neurosurgery, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Bernhard MeyerDepartment of Neurosurgery, Technical University of Munich, School of Medicine, Klinikum rechts der Isar, Munich, Germany.
Daniel ZipsDepartment of Radiation Oncology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID https://orcid.org/0000-0001-5779-9675
Stephanie E CombsDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Institut für Innovative Radiotherapy (iRT), Munich, Germany.
Claus ZimmerDepartment of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
David KaulFaculty of Medicine, HMU Health and Medical University, Potsdam, Germany.
Denise BernhardtDepartment of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Institut für Innovative Radiotherapy (iRT), Munich, Germany.
Benedikt WiestlerDepartment of Diagnostic and Interventional Neuroradiology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.ORCID https://orcid.org/0000-0002-2963-7772

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Meningiomas are the most common primary brain tumors. While most are benign (WHO grade 1) and have a favorable prognosis, up to one-fourth are classified as higher-grade, falling into WHO grade 2 or 3 categories. Recently, an integrated risk score (IRS) pertaining to tumor biology was developed and its prognostic relevance was validated in a large, multicenter study. We hypothesized imaging data to be reflective of the IRS. Thus, we assessed the potential of a machine learning classifier for its noninvasive prediction using preoperative magnetic resonance imaging (MRI). Methods: In total, 160 WHO grade 2 and 3 meningioma patients from 2 university centers were included in this study. All patients underwent surgery with histopathological workup including methylation analysis. Preoperative MRI scans were automatically segmented, and radiomic parameters were extracted. Using a random forest classifier, 3 machine learning classifiers (1 multiclass classifier for IRS and 2 binary classifiers for low-risk and high-risk prediction, respectively) were developed in a training set (120 patients) and independently tested in a hold-out test set (40 patients). Results: Multiclass IRS classification had a test set area under the curve (AUC) of 0.7, mostly driven by the difficulties in clearly separating medium-risk from high-risk patients. Consequently, a classifier predicting low-risk IRS versus medium-/high-risk showed a very high test accuracy of 90% (AUC 0.88). In particular, "sphericity" was associated with low-risk IRS classification. Conclusion: The IRS, in particular molecular low-risk, can be predicted from imaging data with high accuracy, making this important prognostic classification accessible by imaging.

Indexed as

Integrated risk scoreMeningiomaNeuro-oncologyRadiomics

Identifiers

PMID38957161
PMCPMC11217900

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.